The latest first-in-human study initiations will be of interest to followers of D2M Therapeutics, Nested and Volastra.

The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.

The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.

The company takes another project from Taris into phase 3 as it chases a $5bn market.

A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.

Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.